Entering text into the input field will update the search result below

Lilly's Jardiance reduced risk of cardiovascular events in adults with type 2 diabetes

  • Eli Lilly (NYSE:LLY) and Boehringer Ingelheim reports results from EMPA-REG OUTCOME trial assessing Jardiance and placebo, both added to standard of care in adults with type 2 diabetes and established cardiovascular disease.
  • Total cardiovascular events included 3P-MACE (a composite of non-fatal heart attack, non-fatal stroke

Recommended For You

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company